Developmental stage biopharmaceutical company Silo Pharma Inc (Nasdaq:SILO) announced on Tuesday that it has entered into an exclusive global licence agreement to further develop, manufacture and commercialise its Alzheimer's drug SPC-14.
The company aims to expedite drug development using the FDA's streamlined 505(b)(2) pathway, potentially reducing costs and timelines.
Silo CEO Eric Weisblum believes SPC-14 could address a significant unmet medical need. Early pre-clinical data suggests potential benefits in stress reduction and cognitive improvement.
This announcement follows a similar licensing deal for Silo's lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment